Bangladesh
· Delayed Price · Currency is BDT DSE:SQURPHARMA Statistics
Total Valuation
DSE:SQURPHARMA has a market cap or net worth of BDT 179.68 billion. The enterprise value is 110.22 billion.
| Market Cap | 179.68B |
| Enterprise Value | 110.22B |
Important Dates
The next estimated earnings date is Thursday, January 29, 2026.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | Nov 17, 2025 |
Share Statistics
DSE:SQURPHARMA has 886.45 million shares outstanding.
| Current Share Class | 886.45M |
| Shares Outstanding | 886.45M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 44.10% |
| Owned by Institutions (%) | 5.26% |
| Float | 495.49M |
Valuation Ratios
The trailing PE ratio is 7.11.
| PE Ratio | 7.11 |
| Forward PE | n/a |
| PS Ratio | 2.24 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 1.21 |
| P/FCF Ratio | 12.35 |
| P/OCF Ratio | 8.75 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.18, with an EV/FCF ratio of 7.57.
| EV / Earnings | 4.36 |
| EV / Sales | 1.38 |
| EV / EBITDA | 4.18 |
| EV / EBIT | 4.56 |
| EV / FCF | 7.57 |
Financial Position
The company has a current ratio of 11.20, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.20 |
| Quick Ratio | 9.01 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | 0.05 |
| Interest Coverage | 117.87 |
Financial Efficiency
Return on equity (ROE) is 17.98% and return on invested capital (ROIC) is 9.23%.
| Return on Equity (ROE) | 17.98% |
| Return on Assets (ROA) | 8.79% |
| Return on Invested Capital (ROIC) | 9.23% |
| Return on Capital Employed (ROCE) | 13.97% |
| Revenue Per Employee | 5.03M |
| Profits Per Employee | 1.59M |
| Employee Count | 15,937 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 3.05 |
Taxes
In the past 12 months, DSE:SQURPHARMA has paid 5.29 billion in taxes.
| Income Tax | 5.29B |
| Effective Tax Rate | 17.29% |
Stock Price Statistics
The stock price has decreased by -4.02% in the last 52 weeks. The beta is 0.11, so DSE:SQURPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | -4.02% |
| 50-Day Moving Average | 210.66 |
| 200-Day Moving Average | 214.57 |
| Relative Strength Index (RSI) | 33.08 |
| Average Volume (20 Days) | 356,617 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DSE:SQURPHARMA had revenue of BDT 80.13 billion and earned 25.28 billion in profits. Earnings per share was 28.52.
| Revenue | 80.13B |
| Gross Profit | 38.22B |
| Operating Income | 20.93B |
| Pretax Income | 30.57B |
| Net Income | 25.28B |
| EBITDA | 23.12B |
| EBIT | 20.93B |
| Earnings Per Share (EPS) | 28.52 |
Balance Sheet
The company has 58.33 billion in cash and 668.50 million in debt, giving a net cash position of 69.47 billion or 78.37 per share.
| Cash & Cash Equivalents | 58.33B |
| Total Debt | 668.50M |
| Net Cash | 69.47B |
| Net Cash Per Share | 78.37 |
| Equity (Book Value) | 148.48B |
| Book Value Per Share | 167.50 |
| Working Capital | 71.85B |
Cash Flow
In the last 12 months, operating cash flow was 20.54 billion and capital expenditures -5.99 billion, giving a free cash flow of 14.56 billion.
| Operating Cash Flow | 20.54B |
| Capital Expenditures | -5.99B |
| Free Cash Flow | 14.56B |
| FCF Per Share | 16.42 |
Margins
Gross margin is 47.70%, with operating and profit margins of 26.12% and 31.55%.
| Gross Margin | 47.70% |
| Operating Margin | 26.12% |
| Pretax Margin | 38.15% |
| Profit Margin | 31.55% |
| EBITDA Margin | 28.86% |
| EBIT Margin | 26.12% |
| FCF Margin | 18.16% |
Dividends & Yields
This stock pays an annual dividend of 12.00, which amounts to a dividend yield of 5.92%.
| Dividend Per Share | 12.00 |
| Dividend Yield | 5.92% |
| Dividend Growth (YoY) | 9.09% |
| Years of Dividend Growth | 7 |
| Payout Ratio | 38.41% |
| Buyback Yield | n/a |
| Shareholder Yield | 5.92% |
| Earnings Yield | 14.07% |
| FCF Yield | 8.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 23, 2020. It was a forward split with a ratio of 1.05.
| Last Split Date | Nov 23, 2020 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
DSE:SQURPHARMA has an Altman Z-Score of 16.59 and a Piotroski F-Score of 6.
| Altman Z-Score | 16.59 |
| Piotroski F-Score | 6 |